Ontology highlight
ABSTRACT:
SUBMITTER: Yan P
PROVIDER: S-EPMC3448258 | biostudies-literature | 2012 Sep
REPOSITORIES: biostudies-literature
Yan Pearlly P Frankhouser David D Murphy Mark M Tam Hok-Hei HH Rodriguez Benjamin B Curfman John J Trimarchi Michael M Geyer Susan S Wu Yue-Zhong YZ Whitman Susan P SP Metzeler Klaus K Walker Alison A Klisovic Rebecca R Jacob Samson S Grever Michael R MR Byrd John C JC Bloomfield Clara D CD Garzon Ramiro R Blum William W Caligiuri Michael A MA Bundschuh Ralf R Marcucci Guido G
Blood 20120711 12
The outcome of older (≥ 60 years) acute myeloid leukemia (AML) patients is poor, and novel treatments are needed. In a phase 2 trial for older AML patients, low-dose (20 mg/m(2) per day for 10 days) decitabine, a DNA hypomethylating azanucleoside, produced 47% complete response rate with an excellent toxicity profile. To assess the genome-wide activity of decitabine, we profiled pretreatment and post treatment (day 25/course 1) methylomes of marrow samples from patients (n = 16) participating in ...[more]